Skip to main content
Terug
Watch Compare

Pyxis Oncology, Inc.

Datakwaliteit: 100%
PYXS
Nasdaq Manufacturing Chemicals
€ 1,59
▲ € 0,12 (8,16%)
Marktkapitalisatie: 99,90 M
Prijs
€ 1,59
Marktkapitalisatie
99,90 M
Dagbereik
€ 1,43 — € 1,59
52-Weeksbereik
€ 0,87 — € 5,55
Volume
609.602
Openen € 1,46
50D / 200D Gem.
€ 1,47
8,18% above
50D / 200D Gem.
€ 2,12
24,95% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -63,51 M
Capital efficient — spends only 0,06% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-14,17%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-101,80%
Onder sectorgemiddelde (-53,47%)
ROIC-69,56%
Net Margin-574,55%
Op. Margin-609,18%

Veiligheid

Debt / Equity
N/A
Current Ratio4,29
Interest CoverageN/A

Waardering

PE (TTM)
-1,25
Boven sectorgemiddelde (-1,47)
P/B Ratio1,45
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,3 -1,5
P/B 1,5 1,6
ROE % -101,8 -53,5
Net Margin % -574,6 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -14,17% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 13,86 M Net Income (TTM) -79,62 M
ROE -101,80% ROA -69,59%
Gross Margin N/A Operating Margin -609,18%
Net Margin -574,55% Free Cash Flow (TTM) -63,51 M
ROIC -69,56% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,29
Interest Coverage N/A Asset Turnover 0,12
Working Capital 63,69 M Tangible Book Value 66,35 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,25 Forward P/E N/A
P/B Ratio 1,45 P/S Ratio 7,21
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -63,57%
Market Cap 99,90 M Enterprise Value 90,98 M
Per Share
EPS (Diluted TTM) -1,28 Revenue / Share 0,22
FCF / Share -1,01 OCF / Share -1,01
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,06% FCF Conversion 79,77%
SBC-Adj. FCF -76,21 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 13,86 M 16,15 M — — —
Net Income -79,62 M -77,33 M -73,79 M -120,72 M -75,98 M
EPS (Diluted) -1,28 -1,32 -1,85 -3,65 —
Gross Profit — — — — —
Operating Income -84,42 M -89,46 M -82,20 M -123,48 M -69,72 M
EBITDA — — — — —
R&D Expenses 73,70 M 58,75 M 49,59 M 86,13 M 51,05 M
SG&A Expenses — — — — —
D&A 4,51 M 2,98 M 1,93 M 709.000,0 647.000,0
Interest Expense — — — — —
Income Tax 1,39 M -2,16 M — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 91,52 M 157,18 M 173,73 M 211,38 M 280,02 M
Total Liabilities 38,11 M 36,43 M 48,02 M 50,56 M 18,71 M
Shareholders' Equity 53,41 M 120,75 M 125,70 M 160,82 M 261,31 M
Total Debt — — — — —
Cash & Equivalents 15,42 M 19,47 M 9,66 M 179,29 M 274,74 M
Current Assets 72,11 M 132,44 M 124,60 M 186,61 M 278,67 M
Current Liabilities 21,13 M 17,68 M 25,76 M 31,63 M 18,71 M